Canaccord raises Pulse Biosciences stock price target on tech potential By Investing.com
Canaccord has increased its price target for Pulse Biosciences (NASDAQ:PLSE) to $58 from $43, while maintaining a Buy rating. The firm's decision follows a non-deal roadshow with Pulse Biosciences' CEO and CFO, and highlights the company's nanosecond pulse field ablation platform, clinical evidence, and commercial strategy for its atrial fibrillation business. Pulse Biosciences stock has seen significant growth, rising 87.5% since Canaccord initiated coverage in June 2026, and a remarkable 268% year-to-date.
Pulse Biosciences stock gets a higher fair value estimate
Pulse Biosciences (PLSE) has received a higher fair value estimate of USD 54.00 per share, up from USD 45.25, following positive clinical data and upcoming milestones. Despite a Q2 2026 revenue of USD 434,000, falling short of expectations, the company maintains a strong cash position of USD 101.6 million. Clinical trials for its nPulse Vybrance Percutaneous Electrode System are progressing, with the next earnings report due on November 16, 2026.
BTIG sets a USD 70 target for Pulse Biosciences stock
BTIG has initiated coverage on Pulse Biosciences (PLSE) with a Buy rating and a $70 price target, citing the company's nanosecond pulsed field ablation technology and early clinical evidence. This target is above the broader consensus of $50.20. Pulse Biosciences recently achieved a clinical milestone by enrolling its 100th patient in the PRECISE-BTN study, although revenue remains in the early stages, with the company reporting $434,000 in the last quarter.
Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall
Pulse Biosciences stock (PLSE) fell 3.87% to USD 47.90 on October 2, 2026, ahead of a key management meeting with Oppenheimer in San Francisco on October 7-8, 2026. The company reported Q2 2026 revenue of USD 434,000 and an adjusted loss of USD 0.36 per share, missing consensus estimates. Analysts maintain a "Moderate Buy" rating with an average price target of USD 50.20, emphasizing the need for regulatory progress and market adoption of its Nano-Pulse Stimulation technology.
Pulse Biosciences (PLSE) Stock Analysis Report | Ratings, Financials & Performance
This report provides a comprehensive analysis of Pulse Biosciences (PLSE), a bioelectric medicine company, covering its stock performance, financial health, and future growth potential. It details the company's patented Nano-Pulse Stimulation technology and includes Benzinga Edge Rankings, peer comparisons, analyst ratings, and financial statements for investors. The report aims to help identify the stock's strengths and weaknesses for potential buyers and sellers.
BTIG initiates Pulse Biosciences stock coverage with buy rating
BTIG has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a "Buy" rating and a $70.00 price target, aligning with a "Strong Buy" analyst consensus. The company's Nanosecond Pulsed Field Ablation technology has shown promising clinical results, with a U.S. pivotal study underway and potential FDA approval by late 2027 or early 2028. Despite a recent wider-than-expected loss and revenue miss, analysts remain optimistic due to technological advancements and market potential.
Pulse Biosciences stock reports 100 patient trial milestone
Pulse Biosciences has reached a 100-patient milestone in its PRECISE-BTN thyroid nodule study, doubling the initial enrollment goal. The company holds $101.6 million in cash and has secured additional financing capacity, positioning it for continued clinical and commercial development. Despite a recent daily decline, the stock remains in the upper part of its annual range, with investors looking forward to preliminary trial data and regulatory progress for its nPulse Vybrance system.
Is Pulse Biosciences (PLSE) Fully Valued As Its Thyroid Trial Reaches 100 Patients?
Pulse Biosciences (PLSE) has completed enrollment for 100 patients in its PRECISE-BTN thyroid nodule study, with the first participant having reached a 12-month follow-up. Despite recent stock fluctuations, PLSE has seen a significant year-to-date return of 298.1%. The company, valued at approximately US$3.8 billion, is considered 18% overvalued against a fair value of $45.25, with its future growth heavily reliant on pivotal trial outcomes and scaling up from its current US$1.2 million revenue base.
BTIG initiates Pulse Biosciences stock coverage with buy rating
BTIG has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a buy rating and a $70.00 price target, aligning with a "Strong Buy" consensus despite the stock's 284% year-to-date return. The company's Nanosecond Pulsed Field Ablation technology for cardiac ablation shows promising clinical results, with a potential FDA approval by late 2027 or early 2028. While analysts project significant sales growth, InvestingPro's Fair Value suggests the stock may be overvalued at current levels.
BTIG initiates coverage of Pulse Biosciences with Buy rating, $70 price target
BTIG has initiated coverage on Pulse Biosciences (PLSE) with a Buy rating and a $70 price target, suggesting a 32.9% upside from its Sep 22 close. The positive outlook is attributed to the company's innovative Nanosecond Pulsed Field Ablation (nsPFA) technology, which has shown strong clinical results, and its strategic partnership model for U.S. commercialization. This approach is expected to enhance market entry and mitigate financial risks.
BTIG Initiates Pulse Biosciences at Buy With $70 Price Target
BTIG has initiated coverage of Pulse Biosciences (PLSE) with a "Buy" rating and a price target of $70. This new price target is higher than the average analyst target of $54 for the company. The article, however, is a premium piece, requiring a subscription to read the full details.
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences has announced the completion of enrollment in its PRECISE-BTN clinical study, evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for symptomatic benign thyroid nodules. The study successfully enrolled 100 patients across three U.S. clinical sites, doubling its original patient count, and the first patient has already completed their 12-month follow-up. The company plans to present preliminary data soon and full data upon completion of all 12-month follow-ups.
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com
This article is a Form 8K filing for Pulse Biosciences Inc (PLSE) dated September 15. The company's stock symbol is PLSE, and its stock price showed a 3.48% increase. The article mentions that the Form 8K was published on September 15, 2026, at 04:52 p.m.
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences has announced the completion of enrollment for its PRECISE-BTN clinical study, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study successfully enrolled 100 patients across three U.S. sites, doubling its original target. The company plans to present preliminary data from the study at an upcoming medical conference, with full data expected after all patients complete their 12-month follow-up.
Pulse Biosciences enters $85 million equity distribution agreement with Mizuho
Pulse Biosciences (NASDAQ:PLSE) has entered into an equity distribution agreement with Mizuho Securities USA LLC, allowing it to sell up to $85 million of its common stock. This new agreement follows a previous $75 million agreement with Mizuho, under which the company had already sold approximately $68.8 million in shares. The company also terminated an earlier agreement with TD Securities.
Form 8K Pulse Biosciences Inc For: 15 September By Investing.com
This article reports on Pulse Biosciences Inc.'s Form 8K filing for September 15. The brief announcement provides no specific details from the filing but indicates it is a standard regulatory disclosure.
Pulse Biosciences Finalizes Enrollment for PRECISE-BTN Trial Evaluating nPulse Vybrance System
Pulse Biosciences (NASDAQ:PLSE) has successfully completed patient enrollment for its PRECISE-BTN clinical trial, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study expanded from 50 to 100 patients, with enrollment occurring at three U.S. clinical sites. The first patient has also completed their 12-month follow-up, and the trial will assess safety, nodule volume reduction, symptom relief, hormone normalization, and quality of life improvements.
Freedom Capital initiates Pulse Biosciences stock with buy rating By Investing.com
Freedom Capital has initiated coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a $73.00 price target, suggesting a 50% upside from its current trading price of $48.79. The firm highlighted the potential of Pulse Biosciences' nsPFA technology to disrupt the atrial fibrillation ablation market and noted the company's strong financial position. This initiation follows other positive analyst coverage and advancements in the company's clinical trials, despite a recent wider-than-expected loss.
Pulse Biosciences stock hits all-time high at 56.15 USD By Investing.com
Pulse Biosciences Inc. (PLSE) stock reached an all-time high of $56.15, trading just below its 52-week high of $55.37, with a market capitalization of $3.92 billion and a 1-year change of 264.39%. Despite reporting a wider-than-expected loss and lower revenue in Q2, investor optimism stems from progress in its atrial fibrillation trial and other programs, leading to "Buy" ratings and increased price targets from several analysts. InvestingPro suggests the stock may be overvalued at current levels.
Freedom Capital initiates Pulse Biosciences stock with buy rating
Freedom Capital has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and a $73.00 price target, citing the company's nsPFA technology as a potential disruptor in the atrial fibrillation ablation market. The firm highlights Pulse Biosciences' strong cash position and expects NANOPULSE-AF data in Q2 2027, which could lead to potential acquisition interest. This positive outlook follows recent news of a wider-than-expected loss but also faster enrollment in clinical trials and analyst upgrades from Needham and Canaccord.
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock
Pulse Biosciences COO Liane Teplitsky recently purchased $99,971 worth of company stock through open market transactions. These purchases occurred as PLSE stock trades near its 52-week high after a significant year-to-date surge, though InvestingPro analysis suggests it may be overvalued. The company has also reported a wider-than-expected Q2 2026 loss but is making progress in clinical trials and has received positive analyst ratings.
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com
Liane Teplitsky, COO of Pulse Biosciences (NASDAQ:PLSE), recently purchased $99,971 worth of company stock through open market transactions. These purchases occurred as PLSE stock is trading near its 52-week high, having surged 284% year-to-date, though InvestingPro analysis suggests the stock may be overvalued. The company also recently reported a wider-than-expected loss for Q2 2026, but is making progress in clinical trials and regulatory efforts.
Pulse Biosciences COO Liane Teplitsky buys $99,965 in stock
Pulse Biosciences COO Liane Teplitsky recently bought $99,965 worth of company stock, acquiring 2,070 shares in two separate transactions. This insider purchase occurred while the stock is near its 52-week high, despite InvestingPro analysis suggesting it is overvalued. The company also reported a wider-than-expected Q2 loss, though positive investor sentiment remains due to progress in its atrial fibrillation trial and analyst upgrades.
Pulse Biosciences (NASDAQ: PLSE) links CFO options to value and revenue goals
Pulse Biosciences (NASDAQ: PLSE) has granted its Chief Financial Officer, Jon Skinner, 300,000 stock options with an exercise price of $20.93 per share. Half of these options will vest over four years, while the other half are tied to performance goals, including achieving market capitalization between $2 billion and $5 billion and GAAP revenue targets ranging from $48 million to $175 million. This compensation structure aims to align the CFO's incentives with the company's growth and value creation.
Pulse Biosciences stock hits all-time high at 48.92 USD
Pulse Biosciences (PLSE) stock reached an all-time high of $48.92, driven by a 248% year-to-date performance and strong investor confidence in its biosciences innovations. Despite recent misses in Q2 2026 earnings and revenue estimates, analysts anticipate significant revenue growth and have issued "buy" ratings, highlighting progress in clinical trials and technology development. However, InvestingPro suggests caution as the stock appears overvalued and in overbought territory.
Pulse Biosciences stock hits all-time high at 48.92 USD By Investing.com
Pulse Biosciences (PLSE) stock has reached an all-time high of $48.92, reflecting a 1-year return of 186.1% and a year-to-date performance of 248%, pushing its market capitalization to $3.46 billion. Despite this momentum, InvestingPro analysis indicates the stock is overvalued and trading near its 52-week high with an overbought RSI. The company expects significant revenue growth of 429% this year, although profitability is not anticipated yet, and recently missed Q2 2026 earnings and revenue estimates.
Net income before discontinued operations of Pulse Biosciences, Inc. – HAM:6L8
This article presents financial data for Pulse Biosciences, Inc. (HAM:6L8) on TradingView, specifically focusing on its net income before discontinued operations. It highlights that the market was closed with no trades recorded at the time of viewing. The content also lists various features and services offered by TradingView.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences announced that its Compensation Committee granted equity awards to five new employees under the 2017 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These inducement options allow the employees to purchase up to 16,950 shares of Company common stock at an exercise price of $44.92 per share, vesting over four years. This initiative aims to attract and retain talent as the company continues to develop its Nanosecond Pulsed Field Ablation (nano-PFA) technology.
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Bank of America Corp DE has increased its stake in Pulse Biosciences, Inc (NASDAQ:PLSE) by 8.2% in the first quarter, now owning 866,061 shares worth over $18 million. Several other institutional investors also adjusted their positions in PLSE. The article also covers Pulse Biosciences' recent price performance, earnings, and analyst ratings, which currently indicate a "Moderate Buy" consensus.
Pulse Biosciences (PLSE) Launched A $75 Million Offering, Is The Upside Already Priced In?
Pulse Biosciences (PLSE) recently reported wider second-quarter losses and initiated a $75 million equity offering, despite a significant run-up in its share price. The company is advancing its atrial fibrillation nsPFA program, but its current valuation of $46.79 is considered overvalued compared to a narrative fair value of $41.00. Investors are advised to examine key reward and warning signs as the company faces hurdles like ongoing losses and execution risks in converting its pipeline into revenue.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 18, 2026
Pulse Biosciences announced equity inducement grants to five new employees under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the Compensation Committee, involve options to purchase up to 16,950 shares of common stock at an exercise price of $44.92 per share. The options will vest over four years, contingent on continued employment.
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation
Pulse Biosciences (PLSE) has granted equity awards to five new hires, totaling options for 16,950 shares, to attract talent crucial for advancing its medical device technologies. The company exhibits an extremely high Price-to-Sales ratio of 2755.9x, indicating strong market expectations despite its unprofitable and cash-flow-negative status. Its GF Score™ is 30/100, reflecting weak profitability and valuation, though tempered by moderate financial strength and strong momentum, while insider buying signals management confidence.
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Goldman Sachs initiated coverage on Onto Innovation with a Buy rating and a $400 price target, leading a list of five new analyst initiations. Other companies receiving new coverage include Columbia Financial, Target Hospitality, Dave Inc, and Pulse Biosciences, all with bullish ratings and price targets.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. announced that its Compensation Committee granted equity inducement awards to five new employees. These awards, issued on August 13, 2026, consist of stock options to purchase up to 16,000 shares of common stock at an exercise price of $88.88 per share, vesting over four years. The grants were made outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
PULSE BIOSCIENCES INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $58
Needham has initiated coverage on Pulse Biosciences Inc. with a Buy rating. The firm has set a target price of $58 for the company's stock. This report was published by Reuters on August 17, 2026.
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences is developing nanosecond pulsed field ablation (nsPFA) technology as a potential treatment for atrial fibrillation (AFib) and other conditions. CEO Paul LaViolette highlighted the non-thermal nature of nsPFA, which aims to ablate cells without causing inflammation or damage to surrounding tissues, potentially offering significant advantages over current methods. The company is enrolling its Nano-Pulse AF IDE study in the U.S., building on promising European feasibility study results that showed a substantial reduction in AFib failure rates compared to existing technologies.
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed?
Pulse Biosciences recently reported wider net losses for Q2 and H1 2026 and filed for a $75 million at-the-market equity offering, indicating increased cash needs and reliance on equity financing. While the company's stock rose 5.0% post-announcement, these developments highlight potential dilution risks and the need for significant R&D spending to translate into revenue from its nanosecond pulse field ablation platforms. The investment narrative hinges on clinical trial success, with analysts now reconsidering earlier bullish revenue forecasts due to deeper losses and fresh equity.
Needham & Company LLC Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE)
Needham & Company LLC initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a "Buy" rating and a $58 price target, indicating a potential upside of over 30%. Despite missing quarterly earnings and revenue expectations, the company holds a "Moderate Buy" consensus rating from analysts. Institutional investors own a significant portion of the stock, and the company focuses on developing medical devices using its proprietary Tissue NanoPoration (TNP) platform.
Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of "Moderate Buy" by Brokerages
Pulse Biosciences, Inc. (NASDAQ:PLSE) has received a "Moderate Buy" consensus rating from five analysts, with an average 12-month price target of $45.25. The company's stock opened at $44.54, near its 52-week high, and institutional investors hold a significant portion of its shares. Despite positive analyst sentiment, Pulse Biosciences recently reported an adjusted loss of $0.36 per share, missing expectations, and analysts project a full-year loss of $1.29 per share.
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed?
Pulse Biosciences recently reported widened net losses for Q2 and H1 2026 and filed for a US$75 million at-the-market equity offering, signaling increased cash needs. While these developments raise concerns about cash burn and dilution risk, the core investment narrative around its nanosecond pulse field ablation platforms and ongoing clinical trials, such as the NANOPULSE AF study reaching its enrollment midpoint, remains central. The article questions if the new financial details alter the long-term bullish outlook for the company, which anticipates significant revenue growth by 2029.
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns
Pulse Biosciences (PLSE) stock has seen a significant run, returning 431.5% over three years, driven by its atrial fibrillation program. Despite this strong performance, the stock appears expensive based on traditional valuation metrics, trading at a P/B of 31.9x compared to an industry average of 2.6x. The market is pricing in substantial future clinical and commercial success, making the stock highly sensitive to trial outcomes and regulatory approvals.
(PLSE) Risk Channels and Responsive Allocation
This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal strengths, support, and resistance levels.
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued?
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest analyst price target. The most popular valuation narrative suggests the stock is 8.6% overvalued, with a fair value of $41 compared to its recent close of $44.54, based on aggressive assumptions about future revenue and margins.
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Time to Buy?
Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% of the company's shares.
Pulse Biosciences stock reaches all-time high at 46.03 USD By Investing.com
Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting its market capitalization to $3.24 billion, though InvestingPro indicates it is overvalued. Positive investor sentiment is driven by progress in its atrial fibrillation trial and other programs, leading Canaccord to raise its price target to $43.
Pulse Biosciences stock reaches all-time high at 46.03 USD
Pulse Biosciences (PLSE) stock reached an all-time high of $46.03, currently trading at $45.91. This surge represents a 163.78% increase over the past year and 216% year-to-date, pushing its market capitalization to $3.24 billion. Despite recent financial results showing a wider-than-expected loss and lower revenue, investor sentiment remains positive due to progress in clinical trials and a raised price target from Canaccord.
PLSE: nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption
Pulse Biosciences, Inc. (PLSE) is developing next-generation nsPFA technology for AFib treatment, demonstrating high efficacy and efficiency. The company's leadership, strong clinical data, competitive position, and partnership strategy are expected to drive broad clinical adoption. This information is based on an audio transcript from Canaccord Genuity's 46th Annual Growth Conference.
Canaccord Genuity Group Issues Positive Forecast for Pulse Biosciences (NASDAQ:PLSE) Stock Price
Canaccord Genuity Group has increased its price target for Pulse Biosciences (NASDAQ:PLSE) from $32 to $43, reaffirming a "Buy" rating, despite the company reporting weaker-than-expected quarterly results. The stock holds a "Moderate Buy" consensus rating from analysts with an average target of $36. Institutional ownership in Pulse Biosciences remains high at 76.95%, with significant new investments from firms like BlackRock.
Pulse Biosciences (PLSE) After NANOPULSE AF Progress As Valuation Questions Build
Pulse Biosciences (PLSE) is under scrutiny after reporting a wider quarterly net loss and a US$75 million equity offering, despite its NANOPULSE-AF Study reaching its enrollment midpoint. The stock has seen significant gains, but analysts are concerned about its valuation, with a fair value estimate of $30.67 against a current price of $42.41, indicating it might be overvalued. The narrative for growth relies on rapid revenue expansion and improved margins, but execution risks and limited current revenue pose challenges.
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences reported Q2 revenue of $434,000, driven by the acceleration of its nanosecond pulsed field ablation (nsPFA) technology for atrial fibrillation. The company's U.S. NANOPULSE-AF pivotal study is ahead of schedule, with enrollment expected to complete in early October, and it is also advancing its surgical clamp and Vybrance thyroid programs. Despite a widening GAAP net loss of $24.7 million due to increased clinical spending, Pulse Biosciences raised $57.5 million in net proceeds through its at-the-market program, extending its operating runway through planned clinical and regulatory milestones.
